NewLake Capital Partners, Inc. (NLCP) Earnings Call Transcript
August 6, 2026
Earnings Call Speaker Segments
Thanks, operator, and good morning to all of you. I'd like to welcome everyone to New Lake Capital Partners' conference call covering the financial results for the second quarter of 2026. With me today are Anthony Coniglio, our President and Chief Executive Officer, and Lisa Meyer, our Chief Financial Officer. Prior to starting, I want to point out that some of what we say on this call might be deemed forward looking in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 2 thousand. A range of risks and uncertainties could cause actual results to differ materially; for a fuller discussion of those factors, please see the company's filings with the Securities and Exchange Commission, including our Form 10 Q for the quarter ended 06/30/2026. We'll also be citing non GAAP financial measures on this call, among them FFO and AFFO. Reconciliations to the most directly comparable GAAP measures appear in our earnings release. Having said that, I'd now like to hand the call over to Anthony Coniglio, President and Chief Executive Officer. Please go ahead, Anthony.
Thanks, Valter, and good morning to all of you. Over the last few months, we've seen one of the most productive stretches for the cannabis sector in quite a while. Medical cannabis being moved to Schedule III, the ongoing headway being made toward wider reform, and the listings of Trulieve and Glasshouse on the New York Stock Exchange — each of these is a significant milestone signaling the industry's continuing normalization. Additional reform is still required before the industry can enjoy unrestricted entry to The US capital markets, but the advances of the past several months give us encouragement, and we see them as a meaningful move toward an operating environment that is more stable and more sustainable. As I noted on our previous call, medical rescheduling does more than just remove 280E taxation. With DEA registration, registered medical cannabis operators become federally legal businesses. Every one of our tenants running medical only facilities — which accounts for 50% of our portfolio — has told us they have filed applications for DEA registrations. In our view, this marks yet another important step toward greater institutional participation and better access to capital markets, including the possibility of listing on major US exchanges. With that as the backdrop, NewLake posted another solid quarter. On the earnings call, the company reported that revenue and AFFO matched expectations. For the quarter, AFFO landed at 88%, which falls inside the 80% to 90% guidance range and supports a dividend of $0.43 per share. Management noted that the portfolio continues to demonstrate resilience, crediting disciplined underwriting, conservative balance sheet management, and attention to property level performance. Turning to the portfolio, the company said it is still monitoring developments involving its tenant the cannabis. As discussed last quarter, the cannabis filed for bankruptcy in Canada earlier this year and has been working through a court supervised process. The company leases 4 properties to the cannabis, including a dispensary and cultivation facility in Illinois and a dispensary cultivation facility in Massachusetts. On a recent earnings call, we shared that Vireo Growth has agreed to purchase select assets in the cannabis space spanning 5 markets, Illinois and Massachusetts among them. Through and including August rent, The Cannabist is paid up, and we're working closely with The Cannabist as well as other parties to reduce the chance of any rent interruption at our properties. As soon as we have firmer details to provide, stakeholders will receive an update; roughly 1 month of security deposit remains in place across those properties. Turning to investment activity, we were pleased to complete a $2.1 million deal involving a 3.2 thousand square foot dispensary located in Wilder, Kentucky, which C3 Industries will lease; through this transaction we extend our reach into Kentucky's developing medical cannabis sector, and it should add to earnings. What matters even more is that this shows a pipeline that's been getting busier and busier across the last several months. Zooming out, there's a renewed sense of optimism across the industry about chances to put capital to work, chase growth initiatives, and participate in consolidation within the sector. Given that, we're taking a hard look at new investments right now. That said, nothing has changed when it comes to how we underwrite. Discipline and selectivity will continue to guide us, and we'll prioritize protecting capital and risk adjusted returns over expanding merely for expansion's sake. As for the 3 properties we've got on the market for lease, they remain actively marketed. It does take time for re-tenanting opportunities to develop, but both the caliber and the tempo of our conversations have picked up in recent months. As we look to the future, we see a growing set of possible catalysts building up for the industry. Among them are medical rescheduling, movement toward rescheduling cannabis more broadly, chances for plant-touching companies to list on exchanges, the possibility of banking reform, and heightened scrutiny of intoxicating hemp-derived products. Although when these developments will happen and how they will turn out is still unclear, we think the overall trajectory remains positive for the industry. There is also one more subject I want to speak to, since we have gotten quite a few inquiries about it after Trulieve and Glasshouse listed on the New York Stock Exchange. Nothing is being announced at this time, though we are looking closely at whether New Lake could move up to a major exchange. As a reminder to our investors, New Lake already meets the criteria set by both the NYSE and NASDAQ, with the sole exception being those exchanges' limitations on companies tied to cannabis. As the regulatory landscape keeps evolving, we will keep assessing possible routes ahead so that we are ready to move should that chance present itself. No determinations have been reached as of yet, but we do think that wider exchange access would generate added value for our shareholders down the road. One last thing: after the quarter closed, we pushed out the maturity date on our revolver to May 2029, and at the same time we brought our cost of borrowing down and gave ourselves more financial room to maneuver. When money for cannabis companies is still hard to come by and pricey, being able to stretch out that facility on better terms — and keep chasing investments that add value — says a lot about how solid our balance sheet is, how good our portfolio is, and how much faith our lending partners place in what we're building. And before I hand things to Lisa, I want to acknowledge David Weinstein, who left our board at the end of July. David has been with New Lake from the very beginning, when we started the company back in 2019, and he held the chief executive officer role as we made our way into the public markets. The board, our management team, and shareholders all want to express our gratitude to David for the years he gave us and for everything he contributed to this company; we wish him nothing but success going forward. Lisa will now take over and walk everyone through our financial results in greater detail.
Thanks, Anthony, and good morning, everyone. Looking at the second quarter of 2020, we brought in total revenue of $12.1 million, down from $12.9 million during the same period a year earlier. Net income attributable to common stockholders came to $5.9 million, which works out to $0.29 per diluted share. Funds from operation reached $9.9 million, or $0.47 per diluted share, while adjusted funds from operations came in at $10.3 million, or $0.49 per diluted share. During the first 6 months of 2026, total revenue hit $24.4 million, compared with $26.1 million in the equivalent period last year. Net income attributable to stockholders was $11.7 million, or $0.56 per diluted share. Funds from operations came to $19.6 million, or $0.93 per diluted share, and adjusted funds from operations reached $20.4 million, or $0.97 per diluted share. Broadly speaking, the factors driving these year over year results applied to both the 3- and 6-month periods that ended June 30, 2026. Revenue and AFFO took the biggest hit from 3 cultivation facilities sitting available for lease in Pennsylvania, Nevada, and Massachusetts, which lowered rental income and drove up property carrying costs. Several items partly made up for that impact: contractual rent escalations each year that average 2.6% throughout the portfolio, rental income generated by the 2 Ohio dispensaries we picked up in 2025, and rental income tied to funded improvement allowances. On 06/12/2026, our Board of Directors approved a second quarter cash dividend of $0.43 per share. That equals $1.72 per share on an annualized basis. The payout went out on 07/15/2026 to stockholders of record as of 06/30/2026. That comes to an AFFO payout ratio of 88%. Which is still inside our 80% to 90% target range. Our portfolio's earnings power keeps supporting the dividend. Now let's look at the balance sheet. As of 06/30/2026, cash stood at $25.8 million; we continue to keep our leverage profile very conservative. We have just $7.6 million drawn on our $90 million credit facility, a debt to total assets figure of 1.6%, and a debt to EBITDA ratio of roughly 0.2x. During August, we amended the $90 million revolving credit facility, cutting our interest rate by 100 basis points, from Prime plus 1% down to Prime. And pushed the maturity date out to May 2029; we think this amendment makes our balance sheet even stronger by bringing down our cost of capital and extending our maturity date; additionally, in August, as Anthony noted, we bought a dispensary property in Kentucky for about $600 thousand and committed roughly $1.6 million to fund improvements. That property was leased to an existing tenant at the same time. Overall, the Overall, our quarterly results matched what we expected. And we're staying focused on keeping a strong balance sheet while managing risk carefully throughout our portfolio. Given our liquidity, conservative leverage profile, and the fact that no debt maturities come due until 2029, we believe we're well positioned to chase attractive opportunities as cannabis regulations keep evolving. Operator, please open up the line for questions.
Thanks, and good morning to all. Anthony, could we begin with a discussion of lead times? I have Georgia, Virginia, and Texas on my mind. In Georgia's case, flower has supposedly been permitted, legal since July 1. Correct? And from what I understand, businesses there are depleting their flower supplies quite fast. Virginia's start date is July 1 of next year. I ask because production timelines to become operational run 18 months, 24 months, so you would expect those operators to be in touch with you already about leasing candidate properties. It surprises me that we aren't seeing that yet, particularly regarding Georgia and Virginia. I understand Texas might be a slower situation. Thanks.
Yeah. Kentucky serves as a solid example of what we'd anticipate in this climate, where companies show less eagerness for ambitious capacity build out, even in some of these emerging markets; we observe that conversations with us tend to come later than they did, say, during the 2022 to 2023 period, when the stance toward expansion was more aggressive; so yes, we are having some discussions across those states. Still, on the whole, CapEx and expansion are proceeding more slowly into the new states than was the case in, say, the 2012 cohort.
Thanks. That's helpful detail. Regarding the empty buildings — the Ayr cultivation sites in Nevada and Pennsylvania, plus the Revolutionary Clinics grow operation in Massachusetts — could you provide any update? Is selling them the more probable outcome? Perhaps for a different purpose, or even leasing them out for some other use? Or do you think you could find someone to lease them for cannabis growing?
To start, the standard we apply for filling those spaces is maximizing net present value for our shareholders. That means nothing is off the table. We evaluate cannabis uses and non-cannabis ones. Given that these are purpose-built grow facilities, as existing cultivation sites generally are, securing the higher rent a cannabis operator would pay, compared with a non-cannabis one, delivers the greatest benefit to our shareholders. So yes, we explore every option. My sense is that the more time passes without us finding a cannabis tenant with solid credit, the more probable it becomes that we shift toward a non-cannabis tenant or possibly selling the asset.
But regarding that, would you be willing to give odds on those 3? I mean, Nevada appears to be dragging on well beyond what anyone anticipated. I understand that Nevada and Pennsylvania are newer additions. Could you shed a little more light on that?
No. I won't, because things shift so much, Pablo — countless variables play into this. What I can tell you is this: if you consider Pennsylvania, since it remains a medical market, and at some stage it will become one with adult use. it's a market with fewer licenses available. demand for that kind of facility is likely greater than what you'd see, let's say, in Massachusetts. And if you look at, let's say, Nevada, though things moved slowly, hemp strikes us as a genuinely major problem there. And as hemp pulls back and products made from hemp fight for space in the market, in Nevada as hemp keeps spreading, interest has picked up somewhat lately. And so I'd rather not go beyond that when it comes to giving odds, because you can't count anything until it's finished. that's the reason we never announce letters of intent. Signed lease agreements are the only thing we announce.
Thanks. Turning to those Cannabist locations, which are now being taken over by Vireo Growth. I caught what you said about talks still happening, but let me offer a few illustrations. Sometimes when dispensaries get sold, whether due to a restructuring or because the owner defaults, the incoming purchaser acquires the dispensary yet occasionally won't acknowledge the receivables. So anyone holding those receivables — the wholesaler or the vendor supplying that dispensary — winds up eating the loss. What's the precedent there? Though I understand rental property works quite differently, correct? If Vireo intends to keep those dispensaries plus the cultivation, they'd need to honor the leasing agreements and cover the rent. Perhaps I'm pointing out the obvious, but I'm simply attempting to grasp the precedent — not really regarding Vireo specifically, but it appears that whenever these properties get transferred, the new owner must honor the lease agreement, or am I being too naive?
No. I'd say that's right. I'd say that's right. First, let me restate that during my prepared remarks, I told investors The Cannabist has paid rent on all 4 properties through and including August rent. That signals to me a deal can be reached, and nothing's ever done till it is done. Yet these properties clearly carry some value, which is why the rent keeps getting paid. And yes, whenever somebody acquires a license within an operating business, they typically step into that facility and keep paying rent. Occasionally, there might be a negotiation to lower that rent as part of the overall transaction. That's always a possibility in these kinds of transactions. And then I believe what you're alluding to is there have been instances where people bought the licenses and not necessarily the operating businesses. And once you buy the license, you can leave certain assets behind — excuse me, certain liabilities behind — through a Canadian bankruptcy process. So they're complicated and heavily negotiated.
Thanks. One final item from my side. Within the 10 Q, mention is made of the acreage property being guaranteed by Canopy USA. Could you shed additional light on what that looks like in actual operation?
Sure. Back when the deal involving Acreage closed, during 2019 through 2020, a guarantee existed directly from the acreage parent. Because of the restructuring that took place involving Canopy and Acreage — pardon me — which began as Canopy's purchase of Acreage was completed and Canopy USA came into existence, Acreage today has a parent in Canopy USA. Canopy USA doesn't just hold the interest in Acreage; it also holds interest in Wana Jetty, plus shares in TerrAscend. Thus, via conversations and a deal, earlier this year concerning Pennsylvania, we managed to arrange a further guarantee from Canopy USA. As a result, we secured what we regard as added protection for our shareholders through bringing in Canopy USA as a guarantor, rather than relying solely on an Acreage guarantee for the lease.
All right, thanks. Look, I think I'd like to tack on one more thing, Anthony, and I apologize if somebody else is waiting on the Q and A. Queue. Just regarding the macro picture, clearly, I'm always quite keen to hear what you think. So, we're aware of August 17. Correct? Judge Julius needs to, work through every document that comes in, review the hearing, and then produce his report. Question mark how long that's going to take, after which it heads to a DOJ, and then a DA director, has to administrator has to draft the final rule. Right? And, naturally, we're guessing how long that might take. Would you share your thoughts about how long that process is going to take?
That's a guess. I'll give you an answer, though it's a guess. My best estimate is the middle to the end of October; and the reason I land there is when we look at the Administrative Procedures Act and how these sorts of processes function, As you pointed out, the, we need the ALJ recommendation. Well, the post hearing briefs have a deadline of August 17. The ALJ must have time to weigh what gets filed, and we don't anticipate those being filed until the very end. So it will probably take a couple of weeks for the ALJ to finish his report and his recommendation. And so, call that the start of September. Then after his recommendation is issued, there's a what's known as a 30 day exception period in which parties who took part in the hearing get the chance to submit exceptions to whatever the ALJ recommendation is; that brings us into early October, and at that point the DEA must file the final rule and they probably can't do so the day after the exception period closes because they'll need to weigh the exceptions that came in toward the end of that period. So I total all of that up, and there's a great deal of work to be done even though the DEA's likely working on a final rule right now; they do require time to fold in what arrives during that exception period to fold in what the ALJ recommendation is. So that's why I believe the earliest is likely mid October, and so my guess is mid to end of October, And I get somewhat aggressive in that timing only because I do believe in the political overlay that this action carries and that there's probably a wish within the administration to get this finished and get that final rule filed before midterms. And so that's how I reach my conclusion. But I do want to remind everyone once the filing of the final rule happens, it's a 30 day implementation period, and we'll all buckle up for the resulting litigation that will kick off from there. That's right. Thank you very much. That's great color. Thank you, Anthony.
Yeah, hey, good morning. So your property carrying costs went down from one quarter to the next, and I get that those costs wouldn't exist if you'd filled some of that vacant space; but assuming those assets stay empty, what's the right way to think about that for the rest of the year?
The drop in Q2 happened because we got a reimbursement from a former tenant who had been in that space and had moved out; so that just brought property expenses down a bit more than they otherwise would have been, more than they ought to be. My sense is that Q1 is a solid run rate for what those expenses should look like.
Alright, that's useful. From what I understand, Trulieve and Glasshouse both deconsolidated their recreational businesses so they could uplist. I'm just wondering — now that medical has been legalized, are any of your other tenants heading that way?
In order to benefit from the legislation? For most of our remaining tenants that are publicly traded, their operations are more closely tied together with their adult use programs; therefore, what we're observing is that the majority of the rest are choosing to hold off and watch how things develop. Actually, let me say that differently. They are doing things like reverse splits so they can satisfy the listing standards on minimum share price, yet they're not going as far as reorganizing their business, because of what their business looks like or how big the adult use portion is. They expect that rescheduling will be finished later this year, and after that the whole business could be uplisted onto the New York or Nasdaq.
All right. Yeah, that's logical — definitely deferring that call until the second half of the year. And with that in mind, I suppose, are you noticing any increase in deal flow on the medical-only side? And if there is, has there been any shift in cap rates? Or do we simply not know yet?
I'd say there's been no uptick in medical compared with adult use. What's driving the rise in activity is really the opportunities the market is presenting. I don't see people yet steering their business choices just toward medical rather than adult use; and as far as cap rates go, they remain within the same band they've occupied for quite a while. In the market, we haven't witnessed any compression there.
Understood. And apart from cannabis, where it seems like things are moving in a favorable direction, do any other tenants have a caution flag on them, or is everyone continuing to do well?
Our coverage across all four walls continues to appear quite strong. Every one of them gets monitored by us. This being the cannabis sector, a volatile and emerging space, means all of them are under our watch. Those we've called out previously during these calls would be Acreage or The Cannabist. So within the portfolio, those were the names. Compared with, for instance, Cresco, which reported really strong numbers this morning, or Curaleaf, our biggest tenant, which reported last night. Very strong results; and so, you know, as we assess the portfolio, no watch list is published by us as such. We are definitely monitoring the operators in the portfolio that have underperformed their peers historically, like Acreage. Oh, understood.
Alright, I appreciate it — that's all I have.
Sounds good. Thank you, Craig.
Appreciate it, operator, and thanks to all of you for being here with us today. We wish you a great rest of the summer season, and we're eager to be in touch with each of you over the next few months.
Everyone, we appreciate you taking part. That brings an end to the call for today. Please feel free to hang up your phones, and enjoy the rest of your day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete NewLake Capital Partners, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to NewLake Capital Partners, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.